Ani Pharmaceuticals INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
The Vanguard Group filed an amended Schedule 13G, reporting 0% beneficial ownership in ANI Pharmaceuticals Inc. following an internal corporate realignment.
NASDAQ
Millennium Management and affiliated entities have disclosed beneficial ownership of up to 0.3% of ANI Pharmaceuticals, Inc. common stock as of September 30, 2025.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts ANI Pharma Stake to 11.3%
BlackRock, Inc. has reported an 11.3% beneficial ownership stake in ANI Pharmaceuticals Inc. common stock, holding 2,517,424 shares.
NASDAQ
Millennium Management LLC and affiliated entities have disclosed a passive beneficial ownership of 5.2% of ANI Pharmaceuticals, Inc.'s common stock, as detailed in a recent Schedule 13G filing.
NASDAQ
Millennium Management LLC and its affiliates have reported a 3.8% beneficial ownership stake in ANI Pharmaceuticals, Inc. as of March 31, 2025.
NASDAQ
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly disclosed a 5.2% beneficial ownership stake in ANI Pharmaceuticals, Inc., totaling 1,091,003 shares.